• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低分子量肝素和标准肝素预防血栓形成的实验室监测

Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin.

作者信息

Vukovich T, Proidl S, Teufelsbauer H, Kautzky A, Erlacher L, Luger A, Weissel M

机构信息

Department of Medicine II, University of Vienna, Austria.

出版信息

Thromb Res. 1992 Jun 15;66(6):735-43. doi: 10.1016/0049-3848(92)90049-g.

DOI:10.1016/0049-3848(92)90049-g
PMID:1519232
Abstract

This study was made to evaluate assays for monitoring of low dose heparin thromboprophylaxis and to evaluate its efficacy in reduction of hypercoagulation. Patients with medical diseases scheduled for routine thromboprophylaxis were subcutaneously treated with either 5.000 anti XaU low molecular weight (LMW) heparin once daily (n = 20) or 5.000 IU standard (ST) heparin 3 times daily (n = 19). On days 1,2,3, before, 1 and 4 hours after heparin injection APTT, TCT, anti Xa, Heptest, thrombin-antithrombin complexes (TAT), and D-Dimer levels were measured. In the LMW heparin group, median values of APTT and TCT slightly increased after heparin and the ranges of pre- and postinjection values showed extensive overlap. However, values of anti Xa and Heptest markedly increased, showing complete separation of ranges. In the ST heparin group neither APTT, TCT, anti Xa, nor Heptest were significantly different comparing pre- and postheparin values. Half of the patients in both groups had subclinical hypercoagulation at baseline (TAT greater than 5 ng/ml, D-Dimer greater than 200 ng/ml). On day 3 of prophylaxis this percentage was not significantly decreased. Moreover, several patients in both groups increased in TAT and D-Dimer. In the LMWheparin group, negative correlations between body weight and 4 h postinjection heparin levels were found (anti Xa R = -0.50, Heptest R = -0.31) and between 1 h postinjection heparin and TAT and D-Dimer levels 3 h later (TAT-anti Xa R = -0.58, TAT-Heptest R = -0.64, D-Dimer-anti Xa R = -0.32, D-Dimer-Heptest R = -0.33).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本研究旨在评估监测低剂量肝素血栓预防的检测方法,并评估其在降低高凝状态方面的疗效。计划进行常规血栓预防的内科疾病患者,分别接受每日一次皮下注射5000抗Xa单位低分子量(LMW)肝素(n = 20)或每日三次皮下注射5000国际单位标准(ST)肝素(n = 19)的治疗。在第1、2、3天,于肝素注射前、注射后1小时和4小时测量活化部分凝血活酶时间(APTT)、凝血时间(TCT)、抗Xa活性、Heptest、凝血酶 - 抗凝血酶复合物(TAT)以及D - 二聚体水平。在LMW肝素组中,肝素注射后APTT和TCT的中位数略有升高,注射前和注射后的值范围显示出广泛重叠。然而,抗Xa活性和Heptest值显著升高,显示出范围的完全分离。在ST肝素组中,肝素注射前后APTT、TCT、抗Xa活性及Heptest均无显著差异。两组中均有一半患者在基线时存在亚临床高凝状态(TAT大于5 ng/ml,D - 二聚体大于200 ng/ml)。在预防的第3天,这一百分比并未显著降低。此外,两组中的一些患者TAT和D - 二聚体水平升高。在LMW肝素组中,发现体重与注射后4小时肝素水平之间存在负相关(抗Xa活性,R = -0.50;Heptest,R = -0.31),以及注射后1小时肝素与3小时后TAT和D - 二聚体水平之间存在负相关(TAT - 抗Xa活性,R = -0.58;TAT - Heptest,R = -0.64;D - 二聚体 - 抗Xa活性,R = -0.32;D - 二聚体 - Heptest,R = -0.33)。(摘要截短于250字)

相似文献

1
Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin.低分子量肝素和标准肝素预防血栓形成的实验室监测
Thromb Res. 1992 Jun 15;66(6):735-43. doi: 10.1016/0049-3848(92)90049-g.
2
Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.肺内注射低分子量肝素后的抗凝作用及组织因子途径抑制剂
Blood Coagul Fibrinolysis. 1996 Jun;7(4):477-83. doi: 10.1097/00001721-199606000-00008.
3
Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.肝素及其低分子量衍生物新型一步凝血测定法的比较研究
Haemostasis. 1989;19(1):13-20. doi: 10.1159/000215883.
4
Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.肝素和低分子量肝素在治疗深静脉血栓形成中的剂量、抗凝及抗血栓作用
Semin Thromb Hemost. 1997;23(1):83-90. doi: 10.1055/s-2007-996074.
5
Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
Thromb Haemost. 1989 Jun 30;61(3):357-62.
6
Laboratory analysis of blood samples from patients treated with tinzaparin.对接受替扎肝素治疗患者的血样进行实验室分析。
Semin Thromb Hemost. 2004 Feb;30 Suppl 1:49-55. doi: 10.1055/s-2004-823003.
7
Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers.使用凝血激活标志物评估低分子量肝素预防血栓形成的最佳剂量对有血栓形成风险的孕妇进行血栓预防。
Haemostasis. 2001 Mar-Apr;31(2):90-8. doi: 10.1159/000048049.
8
HEPTEST: a suitable method for monitoring heparin during pregnancy.HEPTEST:一种监测孕期肝素的合适方法。
Clin Lab Haematol. 1999 Jun;21(3):193-9. doi: 10.1046/j.1365-2257.1999.00208.x.
9
Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest).使用新型凝血试验(七因子检测)对低分子量肝素(依诺肝素)进行实验室监测。
Haemostasis. 1987;17(3):127-33. doi: 10.1159/000215570.
10
Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.活化部分凝血活酶时间与抗因子 Xa 肝素测定在监测持续静脉输注普通肝素中的应用。
Ann Pharmacother. 2011 Jul;45(7-8):861-8. doi: 10.1345/aph.1Q161. Epub 2011 Jun 28.

引用本文的文献

1
Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.开发和评估一种新型凝血时间检测试验原型,以监测依诺肝素。
Pharm Res. 2012 Jan;29(1):225-35. doi: 10.1007/s11095-011-0537-z. Epub 2011 Aug 6.